| Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2014: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2012: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
|
|---|
| Outline of Final Research Achievements |
We performed amyloid positron emission tomography (PET) with [18F]florbetapir in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and older healthy controls (OHC). A cutoff values for measuring AD-like levels of amyloid for SUVR was well differentially diagnosed and clinically defined AD from OHC. We examined patients with MCI with a history of geriatric depression (GD) and OHC to evaluate the effect of beta-amyloid (Aβ) pathology. Compared to patients without Aβ (GD-Aβ), patients with Aβ (GD+Aβ) did not differ in terms of age, cognitive function, severity of depression and ADL, and brain atrophy. But GD+Aβ had significantly older average age at onset of GD. Our results showed that the rate of Aβ positivity was higher in late-onset GD and that onset-age was associated with SUVR, suggesting that the later the onset of GD, the more Aβ pathology affected its onset.
|
